Trials / Completed
CompletedNCT04403308
ONO-7913 Phase I Study (ONO-7913)
An Open-label, Uncontrolled, Dose Escalation Study in Patients With Advanced or Metastatic Solid Cancers (ONO-7913-01)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ONO-7913 | ONO-7913 will be administered by intravenous continuous infusion during the designated time. |
Timeline
- Start date
- 2020-07-28
- Primary completion
- 2022-01-13
- Completion
- 2022-01-13
- First posted
- 2020-05-27
- Last updated
- 2024-05-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04403308. Inclusion in this directory is not an endorsement.